M.A. Lutz

ISPOR 14th annual European congress research abstractPoster session I: Disease-specific study: Infection – cost studyPIN64 Cost-Effectiveness Analysis of Anti-Pneumococcal Vaccines in Guatemala

infant anti-pneumococcal vaccination. The alternatives compared were: no vaccination (comparator), PCV-7, PCV-10 and PCV-13. The effectiveness measures were: child illness avoided, life years gained (LYs) and quality-adjusted life years (QALYs) gained. Effectiveness and utilities were obtained from literature. Local costs (expressed in 2011

Economic evaluation of apixaban for atrial fibrillation in costa Rica

US) and epidemiology (data from 2009-2011) were obtained from Panamá=s official databases. Univariate sensitivity analysis was performed. The time horizon for total costs was one year and for outcomes was lifetime with a discount rate of 3%. RESULTS: Results show that immunization is cost-saving against no-vaccination. PCV-13 gained the highest number of QALYs (305) against PCV-10 (191) and PCV-7 (168). PCV-13 prevented 629 illnesses and gained 334 LYs. PCV-10 and PCV-7 prevented 392 and 359 illnesses and gained 208 and 182 LY=s, respectively. Total costs of illness with PCV-13, PCV-10, PCV-7 and no vaccination were

PIN7 COST-Effectiveness Analysis Of Anti-Pneumococcal Vaccines Versus No Vaccination In El Salvador

622,445,

Economic evaluation of apixaban for venous thromboembolism in total knee and total hip replacement in Guatemala

777,878,

PIN51 A Cost-Effectiveness Analysis of Linezolid Versus Vancomycin for Ventilator-Associated Pneumonia Patients in Panama

804,978 and

Economic Assessment Of High-Risk Versus Universal Pediatric Pcv13 Vaccination Programs In Costa Rica

1,005,512, respectively. These results were robust to variations in herd immunity and impact adjustments of PCV-10 immunogenicity. CONCLUSIONS: This is the first cost-effectiveness study for antipneumococcal immunization in Panamá. Immunization strategies based on 7, 10 and 13-valent PCV=s may be cost-saving interventions compared to no vaccination. PCV-13 dominates PCV-10 and PCV-7.